PEARL RIVER, N.Y.–(Enterprise WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) these days delivered a thorough, lengthy-time period business enterprise system to travel shareholder worth and also supplied prolonged-expression monetary steering. Acorda has made a extensive-term small business strategy to enhance the worth of the Company, focused on escalating INBRIJA® (levodopa inhalation powder), maximizing AMPYRA® (dalfampridine), and implementing supplemental operational and producing efficiencies. Thanks to the recent Alkermes arbitration award, together with continued fiscal discipline, Acorda has sizeable liquidity, which the Business expects will let it to execute on its enterprise program. Acorda expects to be funds-move good in 2023. The end result of the reverse inventory break up proposal at the upcoming…